The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1086
September 4, 2000
View Complete Issue         Table of Contents 2019 
Photodynamic Therapy With Verteporfin (Visudyne) For Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Photodynamic Therapy With Verteporfin (Visudyne) For Macular Degeneration
September 4, 2000 (Issue: 1086)
Photodynamic therapy with verteporfin (Visudyne--CIVA Vision), an injectable drug, is now being used for treatment of age-related macular degeneration. The drug is a benzoporphyrin derivative that, when activated by light in the presence of oxygen,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Photodynamic Therapy With Verteporfin (Visudyne) For Macular Degeneration
Article code: 1086c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.